Loading stock data…
$6.11-0.16 (-2.55%)
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally.
LENSAR, Inc. in the Healthcare sector is trading at $6.14 with a market capitalization of $82M. Wall Street consensus targets $11.33 (3 analysts), implying a +84.6% move over the next 12 months. The stock is currently near its 52-week low of $4.95, remaining 21.3% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 19 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $16.50M↑ | $13.43M↓ | $16.02M↑ | $14.32M↑ | $13.94M |
| Gross Profit | $9.78M↑ | $6.38M↓ | $6.94M↑ | $6.04M↓ | $7.02M |
| Operating Income | $2.13M↓ | $2.24M↑ | -$4.92M↑ | -$7.58M↓ | -$6.29M |
| Net Income | $3.54M↓ | $36.33M↑ | -$1.46M↑ | -$3.71M↓ | -$1.76M |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, E...